Phenotyping of pulmonary carcinoids and a Ki-67-based grading approach

Virchows Archiv

Volumn 460, Issue 3, 2012, Pages 299-308

  Zahel, Tina ^a   Krysa, Sabine ^b   Herpel, Esther ^a   Stenzinger, Albrecht ^a   Goeppert, Benjamin ^a   Schirmacher, Peter ^a   Hoffmann, Hans ^b   Schnabel, Philipp A ^a   Warth, Arne ^a  

^a UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^b UNIVERSITY OF HEIDELBERG   (Germany)

Author keywords

Biological behavior; Diagnostic marker; Grading; Immunomarkers; Prognosis; Pulmonary carcinoids

Indexed keywords

CD56 ANTIGEN; CD57 ANTIGEN; CD99 ANTIGEN; CHROMOGRANIN A; CYTOKERATIN; EPIDERMAL GROWTH FACTOR RECEPTOR 2; EXCISION REPAIR CROSS COMPLEMENTING PROTEIN 1; KI 67 ANTIGEN; OCTREOTIDE; PROTEIN CK18; PROTEIN KL 1; SOMATOSTATIN RECEPTOR 2; STEM CELL FACTOR RECEPTOR; SYNAPTOPHYSIN; THYMIDYLATE SYNTHASE; THYROID TRANSCRIPTION FACTOR 1; UNCLASSIFIED DRUG; TUMOR MARKER;

ADULT; ARTICLE; CANCER GRADING; CANCER GROWTH; CARCINOID; CLINICAL FEATURE; FEMALE; GASTROINTESTINAL TUMOR; HISTOPATHOLOGY; HUMAN; HUMAN TISSUE; MAJOR CLINICAL STUDY; MALE; MITOSIS; NEUROENDOCRINE TUMOR; PHENOTYPE; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN EXPRESSION; PULMONARY CARCINOID; ADOLESCENT; AGED; BIOSYNTHESIS; CANCER STAGING; IMMUNOHISTOCHEMISTRY; METABOLISM; METHODOLOGY; MIDDLE AGED; MITOSIS INDEX; PATHOLOGY; TISSUE MICROARRAY;

ADOLESCENT; ADULT; AGED; AGED, 80 AND OVER; CARCINOID TUMOR; FEMALE; HUMANS; IMMUNOHISTOCHEMISTRY; KI-67 ANTIGEN; MALE; MIDDLE AGED; MITOTIC INDEX; NEOPLASM GRADING; NEOPLASM STAGING; PHENOTYPE; TISSUE ARRAY ANALYSIS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 84860328164     PISSN: 09456317     EISSN: 14322307     Source Type: Journal    
DOI: 10.1007/s00428-012-1194-2     Document Type: Article

References (38)

1. Jemal A, Siegel R, Xu J, Ward E (2010) Cancer statistics, 2010. CA Cancer J Clin 60(5):277-300. doi:10.3322/caac.20073
2. Travis WD (ed) (2004) WHO classification of tumours: pathology and genetics of tumours of the lung, pleura, thymus and heart, 1st edn. IARC, Lyon
3. Rekhtman N (2010) Neuroendocrine tumors of the lung: an update. Arch Pathol Lab Med 134(11):1628-1638. doi:10.1043/2009-0583- RAR.1
4. WarthA,Herpel E, Krysa S,Hoffmann H, Schnabel PA, Schirmacher P, Mechtersheimer G, Blaker H (2009) Chromosomal instability is more frequent in metastasized than in non-metastasized pulmonary carcinoids but is not a reliable predictor of metastatic potential. Exp Mol Med 41(5):349-353. doi:10.3858/emm.2009.41.5.039
5. Ducrocq X, Thomas P, Massard G, Barsotti P, Giudicelli R, Fuentes P, Wihlm JM (1998) Operative risk and prognostic factors of typical bronchial carcinoid tumors. Ann Thorac Surg 65 (5):1410-1414. doi:S0003497598000836 (Pubitemid 28241705)
6. Warren WH, Gould VE, Faber LP, Kittle CF, Memoli VA (1985) Neuroendocrine neoplasms of the bronchopulmonary tract. A classification of the spectrum of carcinoid to small cell carcinoma and intervening variants. J Thorac Cardiovasc Surg 89(6):819-825 (Pubitemid 15012849)
7. Fink G, Krelbaum T, Yellin A, Bendayan D, Saute M, Glazer M, Kramer MR (2001) Pulmonary carcinoid: presentation, diagnosis, and outcome in 142 cases in Israel and review of 640 cases from the literature. Chest 119(6):1647-1651 (Pubitemid 32744917)
8. Travis WD (2010) Advances in neuroendocrine lung tumors. Ann Oncol 21(Suppl 7):vii65-vii71. doi:10.1093/annonc/mdq380
9. Hage R, de la Riviere AB, Seldenrijk CA, van den Bosch JM (2003) Update in pulmonary carcinoid tumors: a review article. Ann Surg Oncol 10(6):697-704 (Pubitemid 40486903)
10. Warth A, Krysa S, Zahel T, Hoffmann H, Schirmacher P, Schnabel PA, Herpel E (2010) S100 protein positive sustentacular cells in pulmonary carcinoids and thoracic paragangliomas: differential diagnostic and prognostic evaluation. Pathologe 31(5):379-384. doi:10.1007/s00292-010-1293-2
11. Skov BG, Holm B, Erreboe A, Skov T, Mellemgaard A (2010) ERCC1 and Ki67 in small cell lung carcinoma and other neuroendocrine tumors of the lung: distribution and impact on survival. J Thorac Oncol 5(4):453-459. doi:10.1097/ JTO.0b013e3181ca063b
12. Rindi G, Kloppel G, Alhman H, Caplin M, Couvelard A, de Herder WW, Erikssson B, Falchetti A, Falconi M, Komminoth P, KornerM, Lopes JM, McNicolAM, NilssonO, PerrenA, ScarpaA, Scoazec JY, Wiedenmann B (2006) TNM staging of foregut (neuro)endocrine tumors: a consensus proposal including a grading system. Virchows Arch 449(4):395-401. doi:10.1007/s00428-006-0250-1 (Pubitemid 44451313)
13. Travis WD, Rush W, Flieder DB, Falk R, Fleming MV, Gal AA, KossMN (1998) Survival analysis of 200 pulmonary neuroendocrine tumors with clarification of criteria for atypical carcinoid and its separation from typical carcinoid. Am J Surg Pathol 22(8):934-944 (Pubitemid 28364493)
14. Skuladottir H, Hirsch FR, Hansen HH, Olsen JH (2002) Pulmonary neuroendocrine tumors: incidence and prognosis of histological subtypes. A population-based study in Denmark. Lung Cancer 37(2):127-135 (Pubitemid 34831803)
15. Klimstra DS, Modlin IR, Adsay NV, Chetty R, Deshpande V, Gonen M, Jensen RT, Kidd M, Kulke MH, Lloyd RV, Moran C, Moss SF, Oberg K, O'Toole D, Rindi G, Robert ME, Suster S, Tang LH, Tzen CY, Washington MK, Wiedenmann B, Yao J (2010) Pathology reporting of neuroendocrine tumors: application of the Delphic consensus process to the development of a minimum pathology data set. Am J Surg Pathol 34(3):300-313. doi:10.1097/PAS.0b013e3181ce1447
16. Oliveira AM, Tazelaar HD, Myers JL, Erickson LA, Lloyd RV (2001) Thyroid transcription factor-1 distinguishes metastatic pulmonary from well-differentiated neuroendocrine tumors of other sites. Am J Surg Pathol 25(6):815-819 (Pubitemid 32496873)
17. Folpe AL, Gown AM, Lamps LW, Garcia R, Dail DH, Zarbo RJ, Schmidt RA (1999) Thyroid transcription factor-1: immunohistochemical evaluation in pulmonary neuroendocrine tumors. Mod Pathol 12(1):5-8 (Pubitemid 29059159)
18. Sturm N, Rossi G, Lantuejoul S, Papotti M, Frachon S, Claraz C, Brichon PY, Brambilla C, Brambilla E (2002) Expression of thyroid transcription factor-1 in the spectrum of neuroendocrine cell lung proliferations with special interest in carcinoids. Hum Pathol 33(2):175-182 (Pubitemid 34298732)
19. Du EZ, Goldstraw P, Zacharias J, Tiffet O, Craig PJ, Nicholson AG, Weidner N, Yi ES (2004) TTF-1 expression is specific for lung primary in typical and atypical carcinoids: TTF-1-positive carcinoids are predominantly in peripheral location. Hum Pathol 35(7):825-831 (Pubitemid 38903075)
20. La Rosa S, Chiaravalli AM, Placidi C, Papanikolaou N, Cerati M, Capella C (2010) TTF1 expression in normal lung neuroendocrine cells and related tumors: immunohistochemical study comparing two different monoclonal antibodies. Virchows Arch 457(4):497-507. doi:10.1007/s00428-010-0954-0
21. Rindi G, Kloppel G, Couvelard A, Komminoth P, Korner M, Lopes JM, McNicol AM, Nilsson O, Perren A, Scarpa A, Scoazec JY, Wiedenmann B (2007) TNM staging of midgut and hindgut (neuro) endocrine tumors: a consensus proposal including a grading system. Virchows Arch 451(4):757-762. doi:10.1007/s00428-007-0452-1 (Pubitemid 47497934)
22. Mengel M, von Wasielewski R, Wiese B, Rudiger T, Muller- Hermelink HK, Kreipe H (2002) Inter-laboratory and interobserver reproducibility of immunohistochemical assessment of the Ki-67 labelling index in a large multi-centre trial. J Pathol 198 (3):292-299. doi:10.1002/path.1218 (Pubitemid 35277379)
23. Hsu CY, Ho DM, Yang CF, Chiang H (2003) Interobserver reproducibility of MIB-1 labeling index in astrocytic tumors using different counting methods. Mod Pathol 16(9):951-957. doi:10.1097/01.MP.0000084631.64279.BC (Pubitemid 37152026)
24. Dhall D (2009) Interobserver variability in assessing Ki67 proliferative index in gastrointestinal well-differentiated neuroendocrine neoplasms. Mod Pathol 22:116A
25. Kosmidis PA (2004) Treatment of carcinoid of the lung. Curr Opin Oncol 16(2):146-149 (Pubitemid 38402528)
26. Righi L, Volante M, Tavaglione V, Bille A, Daniele L, Angusti T, Inzani F, Pelosi G, Rindi G, Papotti M (2010) Somatostatin receptor tissue distribution in lung neuroendocrine tumours: a clinicopathologic and immunohistochemical study of 218 'clinically aggressive' cases. Ann Oncol 21(3):548-555. doi:10.1093/ annonc/mdp334
27. Volante M, Brizzi MP, Faggiano A, La Rosa S, Rapa I, Ferrero A, Mansueto G, Righi L, Garancini S, Capella C, De Rosa G, Dogliotti L, Colao A, Papotti M (2007) Somatostatin receptor type 2A immunohistochemistry in neuroendocrine tumors: a proposal of scoring system correlated with somatostatin receptor scintigraphy. Mod Pathol 20(11):1172-1182. doi:10.1038/modpathol.3800954 (Pubitemid 47609066)
28. Rusch VW, Klimstra DS, Venkatraman ES (1996) Molecular markers help characterize neuroendocrine lung tumors. Ann Thorac Surg 62(3):798-809, discussion 809-710
29. Rickman OB, Vohra PK, Sanyal B, Vrana JA, Aubry MC, Wigle DA, Thomas CF Jr (2009) Analysis of ErbB receptors in pulmonary carcinoid tumors. Clin Cancer Res 15(10):3315-3324. doi:10.1158/1078-0432.CCR-08-2549
30. Ceppi P, Volante M, Ferrero A, Righi L, Rapa I, Rosas R, Berruti A, Dogliotti L, Scagliotti GV, Papotti M (2008) Thymidylate synthase expression in gastroenteropancreatic and pulmonary neuroendocrine tumors. Clin Cancer Res 14(4):1059-1064. doi:10.1158/1078-0432.CCR-07-1513 (Pubitemid 351302551)
31. Oberg K, Norheim I, Theodorsson E (1991) Treatment of malignant midgut carcinoid tumours with a long-acting somatostatin analogue octreotide. Acta Oncol 30(4):503-507
32. Divisi D, Crisci R (2005) Carcinoid tumors of the lung and multimodal therapy. Thorac Cardiovasc Surg 53(3):168-172. doi:10.1055/s-2005-837539 (Pubitemid 40827255)
33. Nilsson O, Kolby L, Wangberg B, Wigander A, Billig H, William- Olsson L, Fjalling M, Forssell-Aronsson E, Ahlman H (1998) Comparative studies on the expression of somatostatin receptor subtypes, outcome of octreotide scintigraphy and response to octreotide treatment in patients with carcinoid tumours. Br J Cancer 77(4):632-637 (Pubitemid 28059472)
34. Haug AR, Auernhammer CJ, Wangler B, Schmidt GP, Uebleis C, Goke B, Cumming P, Bartenstein P, Tiling R, Hacker M (2010) 68Ga-DOTATATE PET/CT for the early prediction of response to somatostatin receptor-mediated radionuclide therapy in patients with well-differentiated neuroendocrine tumors. J Nucl Med 51 (9):1349-1356. doi:10.2967/jnumed.110.075002
35. Bajetta E, Catena L, Procopio G, De Dosso S, Bichisao E, Ferrari L, Martinetti A, Platania M, Verzoni E, Formisano B, Bajetta R. (2007) Are capecitabine and oxaliplatin (XELOX) suitable treatments for progressing low-grade and high-grade neuroendocrine tumours? Cancer Chemother Pharmacol 59(5):637-642. doi:10.1007/s00280-006-0306-6 (Pubitemid 46295128)
36. Lyda MH, Weiss LM (2000) Immunoreactivity for epithelial and neuroendocrine antibodies are useful in the differential diagnosis of lung carcinomas. Hum Pathol 31(8):980-987. doi:10.1053/hupa.2000.9076
37. Kyoda S, Kinoshita S, Takeyama H, Uchida K, Morikawa T (2008) HER-2 protein overexpression in metastatic breast carcinoma found at autopsy. Jpn J Clin Oncol 38(11):743-747. doi:10.1093/jjco/hyn103
38. Righi L, Papotti MG, Ceppi P, Bille A, Bacillo E, Molinaro L, Ruffini E, Scagliotti GV, Selvaggi G (2010) Thymidylate synthase but not excision repair cross-complementation group 1 tumor expression predicts outcome in patients with malignant pleural mesothelioma treated with pemetrexed-based chemotherapy. J Clin Oncol 28(9):1534-1539. doi:10.1200/JCO.2009.25.9275